Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model

Eiichi Ishida, Jina Lee, Jean S. Campbell, Patrick D. Chakravarty, Yukio Katori, Takenori Ogawa, Lauren Johnson, Anandaroop Mukhopadhyay, William C. Faquin, Derrick T. Lin, Lori J. Wirth, Robert H. Pierce, Sara I. Pai

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Therapeutic cancer vaccines have met limited clinical success. In the setting of cancer, the immune system is either tolerized and/or has a limited tumor-specific T cell repertoire. In this study, we explore whether intratumoral (IT) vaccination with an HPV vaccine can elicit quantitative and qualitative differences in immune response as compared to intramuscular (IM) vaccination to overcome immune resistance in established tumors. We report that IT administration of an HPV-16 E7 peptide vaccine formulated with polyinosinic–polycytidylic acid [poly(I:C)] generated an enhanced antitumor effect relative to IM delivery. The elicited anti-tumor effect with IT vaccination was consistent among the vaccinated groups and across various C57BL/6 substrains. IT vaccination resulted in an increased frequency of PD-1hi TILs, which represented both vaccine-targeted and non-vaccine-targeted tumor-specific CD8+ T cells. Overall, the CD8+/Treg ratio was increased within the tumor microenvironment using IT vaccination. We also assessed transcriptional changes in several immune-related genes in the tumor microenvironment of the various treated groups, and our data suggest that IT vaccination leads to upregulation of a broad complement of immunomodulatory genes, including upregulation of interferon gamma (IFNγ) and antigen presentation and processing machine (APM) components. IT vaccine delivery is superior to traditional IM vaccination routes with the potential to improve tumor immunogenicity, which has potential clinical application in the setting of accessible lesions such as head and neck squamous cell carcinomas (HNSCCs).

Original languageEnglish
Pages (from-to)1273-1286
Number of pages14
JournalCancer Immunology, Immunotherapy
Volume68
Issue number8
DOIs
Publication statusPublished - 2019 Aug 1

Keywords

  • HPV vaccine
  • Immune checkpoints
  • Intratumoral vaccination
  • Lag-3
  • PD-1
  • Tim-3

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model'. Together they form a unique fingerprint.

Cite this